Lv11
30 积分 2025-01-12 加入
A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib in the treatment of US and Chinese patients with EGFR-mutated advanced non-small cell lung cancer
2小时前
已完结
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype
24天前
已完结
Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer
1个月前
已完结
Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer
1个月前
已完结
Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2− Advanced Breast Cancer in the USA?
1个月前
已完结
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Locally Advanced or Metastatic Breast Cancer
1个月前
已完结
皖公网安备34019202002308
